Not dependent on SALUTAS any more: DRL

BUDGET

CNBC-TV18

Markets

14913.05

254.56

NIFTY

4424.25

75.40

Feedback

Make this your Home

You are here : Moneycontrol » News » Results- Company Press Conference

Dr Reddys Laboratories has announced its fourth quarter results. The company's Q4 consolidated net profit was at Rs 103 crore versus 325.5 crore (US GAAP).

Its Q4 consolidated net sales were at Rs 1,320 crore versus Rs 1,557.3 crore(US GAAP).

The company's FY08 consolidated net profit stood at Rs 470 crore. DRL Q4FY07 numbers included Zofran Exclusivity (Rs 270 crore).

GV Prasad, Vice Chairman and CEO, Dr Reddy's Labs said it is not dependent on SALUTAS any more, reports CNBC-TV18. "We will see improvement in the coming quarters. The Custom Pharmaceutical Services, or CPS, , which involves making drugs and ingredients specifically for other companies, business saw a de-growth because of the supply situation in Mexico," it added.

Reditux launched in India and is showing good growth, the management added.

For complete conference, watch video...

Related News: